Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial

CONCLUSIONS AND RELEVANCE: This secondary analysis of the COMPASS trial found that whether assessed by blinded site investigators or adjudicators, dual pathway inhibition significantly reduced CV events among patients with stable atherosclerotic disease compared with aspirin plus placebo. These findings suggest that using investigator-reported events in blinded clinical trials may be a more efficient alternative to adjudication.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01776424.PMID:36409491 | DOI:10.1001/jamanetworkopen.2022.43201

Source: Atherosclerosis - November 21, 2022 Category: Cardiology Authors: Prakriti Gaba Deepak L Bhatt Gilles R Dagenais Jackie Bosch Aldo P Maggioni Petr Widimsky Darryl Leong Keith A A Fox Salim Yusuf John W Eikelboom COMPASS Steering Committee and Investigators Source Type: research